Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All HCQ studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19hcq.org COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Hospitalization 64% Improvement Relative Risk HCQ for COVID-19  Esper et al.  EARLY TREATMENT Is early treatment with HCQ + AZ beneficial for COVID-19? Prospective study of 636 patients in Brazil Lower hospitalization with HCQ + AZ (p=0.024) c19hcq.org Esper et al., Prevent Senior Institute.., Apr 2020 Favors HCQ Favors control

Empirical treatment with hydroxychloroquine and azithromycin for suspected cases of COVID-19 followed-up by telemedicine

Esper et al., Prevent Senior Institute, São Paulo, Brazil
Apr 2020  
  Post
  Facebook
Share
  Source   PDF   All   Meta
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020
 
*, now known with p < 0.00000000001 from 421 studies, recognized in 42 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
3,800+ studies for 60+ treatments. c19hcq.org
636 patients. HCQ+AZ reduced hospitalization 79% when used within 7 days (65% overall). Non-randomized.
risk of hospitalization, 64.0% lower, RR 0.36, p = 0.02, treatment 8 of 412 (1.9%), control 12 of 224 (5.4%), NNT 29.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Esper et al., 15 Apr 2020, prospective, Brazil, preprint, 15 authors, average treatment delay 5.2 days, dosage 800mg day 1, 400mg days 2-7, this trial uses multiple treatments in the treatment arm (combined with AZ) - results of individual treatments may vary.
This PaperHCQAll
Empirical treatment with hydroxychloroquine and azithromycin for suspected cases of COVID-19 followed-up by telemedicine
M.D Rodrigo Barbosa Esper, Ph.D Rafael Souza Da Silva, M.D Fernando Teiichi Costa Oikawa, Ph.D Marcelo Machado Castro, M.D Alvaro Razuk-Filho, Ph.D Pedro Benedito Batista, M.D Sergio Wilhelm Lotze, M.D Cleber Nunes Da Rocha, Roberto De Sá, M.D Cunha Filho, Saulo Emanuel Barbosa De Oliveira, Philipe Leitão Ribeiro, M.D Valéria Cristina, M.D Vigar Martins, Fernando Silva, M.D Braga Bueno, Priscila Ligeiro, M.D Gonçalves Esper, Eduardo Fagundes, Avenida Lourenço Marques, São Paulo -Brazil, Clinicaltrials Gov Identifier
Background: Telemedicine can facilitate patient's assessment with initial flu-like symptoms in the COVID-19 pandemic, moreover it promotes social isolation. Hydroxychloroquine and azithromycin are associated with reduction in COVID-19 patients' viral load. This study aims to assess whether empirical prescription of hydroxychloroquine and azithromycin for patients with suspected COVID-19 is associated with less need for hospitalization Methods: A telemedicine team evaluated suspected COVID-19 outpatients with flu-like symptoms, if no contraindications were detected, treatment with hydroxychloroquine and azithromycin was prescribed after consent from subjects. Patients were monitored daily by telemedicine appointments. Results: Of the 636 symptomatic outpatients, 412 started treatment with hydroxychloroquine and azithromycin and 224 refused medications (control group). Need for hospitalization was 1.9% in the treatment group and 5.4% in the control group (2.8 times greater) and number needed to treat was 28 (NNT = 28). In those who started treatment before versus after the seventh day of symptoms, the need for hospitalization was 1.17% and 3.2%, respectively. Conclusion: Empirical treatment with hydroxychloroquine associated with azithromycin for suspected cases of COVID-19 infection reduces the need for hospitalization (p< 0.001).
Contributors
References
Ai, Yang, Hou, Zhan, Chen et al., Correlation of Chest CT and RT-PCR Testing in Coronavirus Disease
Bmd, SiNAN Sistema de informação de Agravos de Notificação
Bmd, SiVEP-Malária: Sistema de Informação de Vigilância Epidemiológica: notificação de casos
Carlos, Rona, Christophides, Souza-Neto, A comprehensive analysis of malaria transmission in Brazil, Pathog Glob Health
Chen, Hu, Zhang, Jiang, Han et al., Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial
Deresinski, Principles of Antibiotic Therapy in Severe Infections: Optimizing the Therapeutic Approach by Use of Laboratory and Clinical Data, Clinical Infectious Diseases
Devaux, Rolain, Colson, Raoult, New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?, Int J Antimicrob Agents
Dunne, Singh, Shukla, Valecha, Bhattacharyya et al., A double-blind, randomized study of azithromycin compared to chloroquine for the treatment of Plasmodium vivax malaria in India, Am J Trop Med Hyg
Ee, Js, Jp, Rc, In Vitro Inhibition of Human Influenza A Virus Replication by Chloroquine, Virology journal
Gao, Tian, Yang, Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies, Biosci Trends
Gautret, Lagier, Parola, Hoang, Meddeb et al., Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, Int J Antimicrob Agents
Guan, Ni, Hu, Liang, Ou et al., Clinical Characteristics of Coronavirus Disease 2019 in China, N Engl J Med
Hollander, Carr, Virtually Perfect? Telemedicine for Covid-19, N Engl J Med
Huang, Wang, Li, Ren, Zhao et al., Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet
Inciardi, Lupi, Zaccone, Italia, Raffo et al., Cardiac Involvement in a Patient With Coronavirus Disease 2019 (COVID-19), JAMA Cardiol
Jr, Effects of Chloroquine on Viral Infections: An Old Drug Against Today's Diseases?, The Lancet Infectious diseases
Kf, Anti-malaria Drug Chloroquine Is Highly Effective in Treating Avian Influenza A H5N1 Virus Infection in an Animal Model, Cell research
Kj F, Pr, Da, Df, Chloroquine Interferes With dengue-2 Virus Replication in U937 Cells, Microbiology and immunology
Leslie, Mayan, Hasan, Safi, Klinkenberg et al., Sulfadoxine-pyrimethamine, chlorproguanil-dapsone, or chloroquine for the treatment of Plasmodium vivax malaria in Afghanistan and Pakistan: a randomized controlled trial, Jama
Li, Yang, Zhao, Zhi, Wang et al., Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China, Clin Res Cardiol
Liu, Yan, Wan, Xiang, Le et al., Viral dynamics in mild and severe cases of COVID-19, Lancet Infect Dis
Lm, Pp, Fl, Chloroquine, an Endocytosis Blocking Agent, Inhibits Zika Virus Infection in Different Cell Models, Viruses
Lupia, Scabini, Pinna, Perri, Rosa et al., 2019 novel coronavirus (2019-nCoV) outbreak: A new challenge, J Glob Antimicrob Resist
Lurie, Carr, The Role of Telehealth in the Medical Response to Disasters, JAMA Intern Med
Mcchesney, Animal toxicity and pharmacokinetics of hydroxychloroquine sulfate
Mehta, Mcauley, Brown, Sanchez, Tattersall et al., COVID-19: consider cytokine storm syndromes and immunosuppression, Lancet
Naing, Aung, Win, Wah, Efficacy and safety of chloroquine for treatment in patients with uncomplicated Plasmodium vivax infections in endemic countries, Trans R Soc Trop Med Hyg
Ni, Ee, Yb, Chloroquine for Influenza Prevention: A Randomised, Double-Blind, Placebo Controlled Trial, The Lancet Infectious diseases
Reyburn, New WHO guidelines for the treatment of malaria, Bmj
Touret, De Lamballerie, Of chloroquine and COVID-19, Antiviral Res
Vr, In Vitro Inhibition of Severe Acute Respiratory Syndrome Coronavirus by Chloroquine, Biochemical and biophysical research communications
Walsh, Shirley, Wrong, Unwin, Urinary acidification assessed by simultaneous furosemide and fludrocortisone treatment: an alternative to ammonium chloride, Kidney Int
Zhou, Dai, Tong, COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression, J Antimicrob Chemother
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit